Yongyu Liu

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

Dongsheng Yue, Shidong Xu, Qun Wang et al. · The Lancet Respiratory Medicine · 2018 · 293 citations

Medicine, Oncology, Pharmacology +13

Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity

Yu Chen, Yaguo Wang, Joy Fleming et al. · medRxiv · 2020 · 234 citations · Full text

Veterinary Medicine, Infectious Diseases, Infectious Disease Epidemiology +12

Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non–Small-Cell Lung Cancer

Dongsheng Yue, Shidong Xu, Qun Wang et al. · Journal of Clinical Oncology · 2022 · 63 citations

Medicine, Oncology, Pharmacology +16

Thymectomy versus tumor resection for early-stage thymic malignancies: a Chinese Alliance for Research in Thymomas retrospective database analysis

Zhitao Gu, Jianhua Fu, Yi Shen et al. · Journal of Thoracic Disease · 2016 · 57 citations · Full text

Medicine, Oncology, Surgery +12

Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry

Shinya Goto, Pantep Angchaisuksiri, Jean‐Pierre Bassand et al. · Journal of the American Heart Association · 2019 · 55 citations · Full text

Medicine, Cardiology, Nephrology +17